0001964738-26-000024
SEC filingSolventum's Q1 2026 results reflect revenue decline and sharp profit compression due to tariff-driven cost inflation and separation-related expenses, with free cash flow turning deeply negative.
Solventum's first quarter 2026 results were impacted by higher product costs due to tariffs and other inflation, including freight, which weighed on profitability across segments. Revenue declined 3.0% to $2.0 billion compared to the prior year period, as growth from new products and pricing was more than offset by cost-driven headwinds and changing market conditions in certain product lines. Gross profit decreased 1.5% to $1.1 billion, with gross margin contracting slightly to 54.7% from 53.8% in the prior year, as benefits from price and product mix were partially offset by higher input costs.
While segment-level results are not separately disclosed in this filing, the business context indicates that MedSurg segment operating income margin decreased due to higher product costs from tariffs and freight, which offset volume growth. In contrast, Dental and Health Information Systems (HIS) segments experienced operating income margin expansion, benefiting from price, volume, and savings programs, including Transform for the Future, partially offset by tariffs and inflation. Clinician productivity solutions declined primarily due to changing market conditions.
Net cash provided by operating activities was negative $189.0 million in the first quarter of 2026, compared to positive $29.0 million in the prior year, driven by working capital outflows and lower net income. Capital expenditures were $84.0 million, down from $109.0 million in the prior year. Free cash flow was negative $273.0 million, reflecting the operating cash flow deficit and capital spending. The company's cash position reflects business results and a global cash management strategy that leverages liquidity management along with analyzing economic factors and tax considerations.